Industry news that matters to you.  Learn more

St. Gallen International Breast Cancer Guidelines for the Third Time Distinguish Oncotype DX as the Only Multi-Gene Test Validated to Predict Chemotherapy Benefit

Genomic Health (Nasdaq: GHDX) recently announced that the 14th St. Gallen International Breast Cancer Conference Expert Panel, for the third time, recognized the Oncotype DX® breast cancer test for its ability to provide not only prognostic but also predictive information regarding the likelihood of chemotherapy benefit for patients with early-stage, estrogen receptor-positive, invasive breast cancer. Oncotype DX was the only multi-gene test accepted with a strong majority of panellists supporting it as a predictive tool to guide chemotherapy treatment decision making. The new guidelines were recently published online in the Advance Access section of Annals of Oncology and will appear in a future print issue.

Following NICE’s Exclusive Recommendation, NHS England Agrees to Access Program for Oncotype DX Breast Cancer Test

Genomic Health, Inc. (Nasdaq: GHDX) recently announced that, as of April 1, 2015, the Oncotype DX® test will be available to eligible breast cancer patients through the National Health Service (NHS) in England as the only multi-gene breast cancer test recommended by the National Institute for Health and Care Excellence (NICE) for use as an option to assist in chemotherapy treatment decision-making.

Oncotype DX DCIS Score Represents Breakthrough in Personalizing Treatment of Pre-Invasive Breast Cancer

Genomic Health, Inc. (Nasdaq: GHDX) recently announced positive results from the second large clinical validation study of Oncotype DX® in patients with a pre-invasive form of breast cancer known as DCIS (ductal carcinoma in situ). The study, conducted by the Ontario DCIS Study Group of Sunnybrook Health Sciences Centre in Canada, reconfirmed that the Oncotype DX DCIS Score™ is a strong predictor of local recurrence, which could be either invasive breast cancer or DCIS (p<0.001).

Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics

Genomic Health, Inc. (Nasdaq: GHDX) recently announced that PharmacoEconomics published positive results from a health economic analysis suggesting that use of the Oncotype® DX colon cancer test may result in a significant reduction in direct medical costs and improve patient quality of life by helping them avoid side effects of unnecessary treatment.

Multiple Studies Presented at ASCO Annual Meeting Demonstrate Unique, Practice-Changing Impact of Oncotype DX to Optimize Cancer Care

Genomic Health, Inc. (Nasdaq: GHDX) today announced results of six studies being presented at the 2014 American Society of Clinical Oncology ASCO Annual Meeting taking place May 30 – June 3 in Chicago, underscoring the practice-changing value of Oncotype DX in pre-invasive and invasive breast cancer and colon cancer.